Synonym
FOY 251; FOY251; FOY-251; FOY-251 mesylate;
IUPAC/Chemical Name
4-[[4-[(Aminoiminomethyl)amino]benzoyl]oxy]-benzeneacetic Acid Monomethanesulfonate
InChi Key
JXMOPIDYHUYOED-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H15N3O4.CH4O3S/c17-16(18)19-12-5-3-11(4-6-12)15(22)23-13-7-1-10(2-8-13)9-14(20)21;1-5(2,3)4/h1-8H,9H2,(H,20,21)(H4,17,18,19);1H3,(H,2,3,4)
SMILES Code
O=C(O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
409.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Albarazanji K, Jennis M, Cavanaugh CR, Lang W, Singh B, Lanter JC, Lenhard
JM, Hornby PJ. Intestinal serine protease inhibition increases FGF21 and
improves metabolism in obese mice. Am J Physiol Gastrointest Liver Physiol. 2019
May 1;316(5):G653-G667. doi: 10.1152/ajpgi.00404.2018. Epub 2019 Mar 28. PMID:
30920846; PMCID: PMC7054636.
2: Kosinsky Y, Peskov K, Stanski DR, Wetmore D, Vinetz J. Semi-Mechanistic
Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy
against SARS-CoV-2 in COVID-19. Microbiol Spectr. 2022 Apr 27;10(2):e0216721.
doi: 10.1128/spectrum.02167-21. Epub 2022 Apr 12. PMID: 35412356; PMCID:
PMC9047529.
3: Beckh K, Weidenbach H, Weidenbach F, Müller R, Adler G. Hepatic and
pancreatic metabolism and biliary excretion of the protease inhibitor camostat
mesilate. Int J Pancreatol. 1991 Nov-Dec;10(3-4):197-205. doi:
10.1007/BF02924157. PMID: 1787334.
4: Beckh K, Göke B, Müller R, Arnold R. Elimination of the low-molecular weight
proteinase inhibitor camostate (FOY 305) and its degradation products by the rat
liver. Res Exp Med (Berl). 1987;187(6):401-6. doi: 10.1007/BF01852177. PMID:
3441682.
5: Maekawa A, Kakizoe Y, Miyoshi T, Wakida N, Ko T, Shiraishi N, Adachi M,
Tomita K, Kitamura K. Camostat mesilate inhibits prostasin activity and reduces
blood pressure and renal injury in salt-sensitive hypertension. J Hypertens.
2009 Jan;27(1):181-9. doi: 10.1097/hjh.0b013e328317a762. PMID: 19145783.
6: Shrimp JH, Kales SC, Sanderson PE, Simeonov A, Shen M, Hall MD. An Enzymatic
TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors
as Potential Treatment of COVID-19. bioRxiv [Preprint]. 2020 Aug
6:2020.06.23.167544. doi: 10.1101/2020.06.23.167544. Update in: ACS Pharmacol
Transl Sci. 2020 Sep 07;3(5):997-1007. doi: 10.1021/acsptsci.0c00106. PMID:
32596694; PMCID: PMC7315994.
7: Shrimp JH, Kales SC, Sanderson PE, Simeonov A, Shen M, Hall MD. An Enzymatic
TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors
as Potential Treatment of COVID-19. ACS Pharmacol Transl Sci. 2020 Sep
7;3(5):997-1007. doi: 10.1021/acsptsci.0c00106. PMID: 33062952; PMCID:
PMC7507803.
8: Chen J, Liu C, Shan W, Xiao Z, Guo H, Huang Y. Enhanced stability of oral
insulin in targeted peptide ligand trimethyl chitosan nanoparticles against
trypsin. J Microencapsul. 2015;32(7):632-41. doi: 10.3109/02652048.2015.1065920.
Epub 2015 Sep 24. PMID: 26401551.
